Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

cation in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "10
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... CORONA, Calif. , Sept. 22, 2014  AVT, ... in automated retailing systems and custom vending machines, announced ... Opticwash Pro Unit. This new, smaller sized unit is ... Professional (ECP) practices. According to industry statistics, ... Opticwash is the world,s first ...
(Date:9/22/2014)... 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... Emory University, presented long-term follow up data on the ... in the treatment of amyotrophic lateral sclerosis (ALS or ... at the Annual Symposium on ALS of the Foundation ... Friday, and was not open to the public, covered ...
(Date:9/22/2014)... N.J. , Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... fourth quarter and fiscal 2014 ended July 31, 2014 on ... conference call to discuss the results at 11:00 AM ET. ... , Chairman; Andrew A. Krakauer , President and CEO; ... Craig A. Sheldon , Senior Vice President, CFO and ...
Breaking Medicine Technology:Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 ... intensive care units (NICU) set up private rooms for parents ... Researchers at one children,s hospital found that preemies gained ... their NICU switched from the traditional "open-bay" layout to private ... in the journal Pediatrics , add to evidence that ...
(Date:9/22/2014)... Alan Mozes HealthDay Reporter ... Many American parents are aware of online physician-rating sites, and ... for their children, according to a new national study. ... parents -- further suggest that negative online ratings may dissuade ... been recommended by a neighbor. Conversely, a positive online ...
(Date:9/22/2014)... whole eye transplant seems futuristic, if not impossible. ... Department of Defense, researchers at University of California, ... make implantation of an entire, functional eye a ... a holy grail for vision restoration," said Jeffrey ... co-recipient with colleagues at University of Pittsburg Medical ...
(Date:9/22/2014)... scientists have found that an anticonvulsant drug may help ... Although dozens of antibiotics target what bacteria do, their ... bacteria are created, and they found there is a ... important as there is growing concern worldwide about how ... The World Health Organization has declared that antibiotic resistance ...
(Date:9/22/2014)... PITTSBURGH, PA (PRWEB) September 22, 2014 ... caring for patients to the problem of side-sleeping. "My ... my side, so I designed a solution to this ... fall asleep comfortably than to have your arm 'fall ... sleep on his or her side more comfortably. It ...
Breaking Medicine News(10 mins):Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 2Health News:Many Parents Use Online Ratings to Pick a Pediatrician, Study Finds 3Health News:Looking ahead: Whole eye transplant under development 2
... body of basic animal research and studies of abused ... for the hypothesis that individuals with particular genotypes are ... with the abuse of alcohol and other substances. ... assume that these genotypes identify people who are predestined ...
... Board of Directors Audit Committee Members and Complies with ... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today ... J. Wilson as vice president of finance and principal ... team. She brings over twenty years of finance ...
... of Suntan Lotions, Reducing Risk of Deadly Skin Cancer ... & Prevention MonthNEW YORK, April 29 The ... people avoid overexposure to harmful ultraviolet radiation from the ... all across America reduce the risk of skin cancer ...
... 23-month-old child in Texas; CDC warns more deaths are ... 23-month-old child in Texas has become the first U.S. ... officials said Wednesday morning. , Dr. Richard Besser, acting ... Prevention, confirmed the death. No other details on the ...
... Dr. Gordon Norman presents overview of US healthcare ... Federation of Health Plans Meeting in Boston- Noted ... value for its healthcare investment- Emphasized greater coordination ... resolve today,s healthcare challenges MARIETTA, Ga., April 29 ...
... & Mentally IllNEW YORK, April 29 May marks ... it, philanthropic-minded New Yorkers will raise money for Weston ... and physically disabled. As federal and state funding ... the current economy, supporters will raise funds amidst live ...
Cached Medicine News:Health News:Genetic risk for anxiety does not have to be destiny 2Health News:PDL BioPharma Appoints Karen J. Wilson as Vice President, Finance and Principal Accounting Officer 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 2Health News:Easy-to-Use Wristband Tells You When to Apply Sunscreen - and When to Hit the Shade 3Health News:U.S. Reports First Swine Flu Death 2Health News:U.S. Reports First Swine Flu Death 3Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 2Health News:Alere's Dr. Gordon Norman Highlights Challenges and Promising Solutions to U.S. Healthcare System to International Health Insurance Executives 3Health News:Weston United Celebrates Mental Health Month on May 19th 2
... Human Insulin-like growth factor binding protein-2 ... (further IGFBPs have been proposed) which specifically ... and IGF-II. The binding affinity of IGFBP-2 ... higher than for IGF-I [1], suggesting a ...
... Insulin-like growth factor binding protein-2 (IGFBP-2) is ... have been proposed) which specifically bind and ... The binding affinity of IGFBP-2 for IGF-II ... for IGF-I [1], suggesting a role in ...
... Androstenedione, produced in the adrenal gland and ... testosterone and estrone, both of which may ... relatively weak androgenic activity, estimated at ~(less ... [1]. However, serum androstenedione levels often exceed ...
... proteins that suppress the secretion of FSH ... consists of two distinct chains, or subunits ... consists of the alpha-subunit and betaA-subunit. Inhibin ... Only the dimeric forms of the molecule, ...
Medicine Products: